158 related articles for article (PubMed ID: 32215185)
1. Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss.
Owusu-Brackett N; Zhao M; Akcakanat A; Evans KW; Yuca E; Dumbrava EI; Janku F; Meric-Bernstam F
Oncotarget; 2020 Mar; 11(11):969-981. PubMed ID: 32215185
[No Abstract] [Full Text] [Related]
2. Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.
Hancox U; Cosulich S; Hanson L; Trigwell C; Lenaghan C; Ellston R; Dry H; Crafter C; Barlaam B; Fitzek M; Smith PD; Ogilvie D; D'Cruz C; Castriotta L; Wedge SR; Ward L; Powell S; Lawson M; Davies BR; Harrington EA; Foster E; Cumberbatch M; Green S; Barry ST
Mol Cancer Ther; 2015 Jan; 14(1):48-58. PubMed ID: 25398829
[TBL] [Abstract][Full Text] [Related]
3. Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors.
Lynch JT; Polanska UM; Delpuech O; Hancox U; Trinidad AG; Michopoulos F; Lenaghan C; McEwen R; Bradford J; Polanski R; Ellston R; Avivar-Valderas A; Pilling J; Staniszewska A; Cumberbatch M; Critchlow SE; Cruzalegui F; Barry ST
Clin Cancer Res; 2017 Dec; 23(24):7584-7595. PubMed ID: 28972046
[No Abstract] [Full Text] [Related]
4. AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20).
Suh KJ; Ryu MH; Zang DY; Bae WK; Lee HS; Oh HJ; Kang M; Kim JW; Kim BJ; Mortimer PGS; Kim HJ; Lee KW
Oncologist; 2023 Sep; 28(9):e823-e834. PubMed ID: 37036671
[TBL] [Abstract][Full Text] [Related]
5. Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors.
Lynch JT; Polanska UM; Hancox U; Delpuech O; Maynard J; Trigwell C; Eberlein C; Lenaghan C; Polanski R; Avivar-Valderas A; Cumberbatch M; Klinowska T; Critchlow SE; Cruzalegui F; Barry ST
Mol Cancer Ther; 2018 Nov; 17(11):2309-2319. PubMed ID: 30097489
[TBL] [Abstract][Full Text] [Related]
6. Dual inhibition of MEK and PI3Kβ/δ-a potential therapeutic strategy in PTEN-wild-type docetaxel-resistant metastatic prostate cancer.
Ruiz de Porras V; Bernat-Peguera A; Alcon C; Laguia F; Fernández-Saorin M; Jiménez N; Senan-Salinas A; Solé-Blanch C; Feu A; Marín-Aguilera M; Pardo JC; Ochoa-de-Olza M; Montero J; Mellado B; Font A
Front Pharmacol; 2024; 15():1331648. PubMed ID: 38318136
[No Abstract] [Full Text] [Related]
7. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
8. TAK228 enhances antitumor activity of eribulin in triple negative breast cancer.
Owusu-Brackett N; Evans KW; Akcakanat A; Yuca E; Tapia C; Rizvi YQ; Dumbrava EI; Janku F; Meric-Bernstam F
Oncotarget; 2019 Aug; 10(49):5011-5019. PubMed ID: 31489111
[No Abstract] [Full Text] [Related]
9. The use of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) as a pathway-specific biomarker with AZD8186, a PI3Kβ/δ inhibitor.
Maynard J; Emmas SA; Blé FX; Barjat H; Lawrie E; Hancox U; Oakes D; Polanska UM; Barry ST
EJNMMI Res; 2016 Dec; 6(1):62. PubMed ID: 27515445
[TBL] [Abstract][Full Text] [Related]
10. mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphoma.
Xu W; Berning P; Erdmann T; Grau M; Bettazová N; Zapukhlyak M; Frontzek F; Kosnopfel C; Lenz P; Grondine M; Willis B; Lynch JT; Klener P; Hailfinger S; Barry ST; Lenz G
Leukemia; 2023 Jan; 37(1):178-189. PubMed ID: 36352190
[TBL] [Abstract][Full Text] [Related]
11. A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors.
Choudhury AD; Higano CS; de Bono JS; Cook N; Rathkopf DE; Wisinski KB; Martin-Liberal J; Linch M; Heath EI; Baird RD; García-Carbacho J; Quintela-Fandino M; Barry ST; de Bruin EC; Colebrook S; Hawkins G; Klinowska T; Maroj B; Moorthy G; Mortimer PG; Moschetta M; Nikolaou M; Sainsbury L; Shapiro GI; Siu LL; Hansen AR
Clin Cancer Res; 2022 Jun; 28(11):2257-2269. PubMed ID: 35247924
[TBL] [Abstract][Full Text] [Related]
12. Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.
Bonnevaux H; Lemaitre O; Vincent L; Levit MN; Windenberger F; Halley F; Delorme C; Lengauer C; Garcia-Echeverria C; Virone-Oddos A
Mol Cancer Ther; 2016 Jul; 15(7):1460-71. PubMed ID: 27196754
[TBL] [Abstract][Full Text] [Related]
13.
Terzo EA; Lim AR; Chytil A; Chiang YC; Farmer L; Gessner KH; Walker CL; Jansen VM; Rathmell WK
Oncotarget; 2019 Jan; 10(6):647-659. PubMed ID: 30774762
[TBL] [Abstract][Full Text] [Related]
14. A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.
Desroys du Roure P; Lajoie L; Mallavialle A; Alcaraz LB; Mansouri H; Fenou L; Garambois V; Rubio L; David T; Coenon L; Boissière-Michot F; Chateau MC; Ngo G; Jarlier M; Villalba M; Martineau P; Laurent-Matha V; Roger P; Guiu S; Chardès T; Gros L; Liaudet-Coopman E
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38290768
[TBL] [Abstract][Full Text] [Related]
15. E-cadherin downregulation sensitizes PTEN-mutant tumors to PI3Kβ silencing.
Millán-Uclés Á; Zuluaga S; Marqués M; Vallejo-Díaz J; Sanz L; Cariaga-Martínez AE; Real FX; Carrera AC
Oncotarget; 2016 Dec; 7(51):84054-84071. PubMed ID: 27863432
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.
Sangai T; Akcakanat A; Chen H; Tarco E; Wu Y; Do KA; Miller TW; Arteaga CL; Mills GB; Gonzalez-Angulo AM; Meric-Bernstam F
Clin Cancer Res; 2012 Oct; 18(20):5816-28. PubMed ID: 22932669
[TBL] [Abstract][Full Text] [Related]
17. PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer.
Rajput S; Guo Z; Li S; Ma CX
Oncotarget; 2019 Jun; 10(38):3667-3680. PubMed ID: 31217901
[TBL] [Abstract][Full Text] [Related]
18. PI3Kβ controls immune evasion in PTEN-deficient breast tumours.
Bergholz JS; Wang Q; Wang Q; Ramseier M; Prakadan S; Wang W; Fang R; Kabraji S; Zhou Q; Gray GK; Abell-Hart K; Xie S; Guo X; Gu H; Von T; Jiang T; Tang S; Freeman GJ; Kim HJ; Shalek AK; Roberts TM; Zhao JJ
Nature; 2023 May; 617(7959):139-146. PubMed ID: 37076617
[TBL] [Abstract][Full Text] [Related]
19. AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors.
Dunn S; Eberlein C; Yu J; Gris-Oliver A; Ong SH; Yelland U; Cureton N; Staniszewska A; McEwen R; Fox M; Pilling J; Hopcroft P; Coker EA; Jaaks P; Garnett MJ; Isherwood B; Serra V; Davies BR; Barry ST; Lynch JT; Yusa K
Oncogene; 2022 Nov; 41(46):5046-5060. PubMed ID: 36241868
[TBL] [Abstract][Full Text] [Related]
20. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3Kβ and PI3Kδ for the treatment of PTEN-deficient cancers.
Barlaam B; Cosulich S; Degorce S; Fitzek M; Green S; Hancox U; Lambert-van der Brempt C; Lohmann JJ; Maudet M; Morgentin R; Pasquet MJ; Péru A; Plé P; Saleh T; Vautier M; Walker M; Ward L; Warin N
J Med Chem; 2015 Jan; 58(2):943-62. PubMed ID: 25514658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
